| 000 | 01724 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250514034417.0 | ||
| 264 | 0 | _c20021001 | |
| 008 | 200210s 0 0 eng d | ||
| 022 | _a0043-5325 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHaas, Martin | |
| 245 | 0 | 0 |
_aAntioxidant treatment of therapy-resistant idiopathic membranous nephropathy with probucol: a pilot study. _h[electronic resource] |
| 260 |
_bWiener klinische Wochenschrift _cFeb 2002 |
||
| 300 |
_a143-7 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Multicenter Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aAntioxidants _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlomerulonephritis, Membranous _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKidney Function Tests |
| 650 | 0 | 4 |
_aLipid Peroxidation _xdrug effects |
| 650 | 0 | 4 |
_aLovastatin _xtherapeutic use |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aProbucol _xtherapeutic use |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aProteinuria _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMayer, Gert | |
| 700 | 1 | _aWirnsberger, Gerhard | |
| 700 | 1 | _aHolzer, Herwig | |
| 700 | 1 | _aRatschek, Manfred | |
| 700 | 1 | _aNeyer, Ullrich | |
| 700 | 1 | _aNeuweiler, Josef | |
| 700 | 1 | _aKramar, Reinhard | |
| 700 | 1 | _aSchneider, Brigitte | |
| 700 | 1 | _aBreiteneder-Geleff, Silvana | |
| 700 | 1 | _aRegele, Heinrich M | |
| 700 | 1 | _aHörl, Walter H | |
| 700 | 1 | _aKerjaschki, Dontscho | |
| 773 | 0 |
_tWiener klinische Wochenschrift _gvol. 114 _gno. 4 _gp. 143-7 |
|
| 999 |
_c11956478 _d11956478 |
||